Diagnosis and screening for familial hypercholesterolaemia: Finding the patients, finding the genes

Annals of Clinical Biochemistry

Volumn 43, Issue 6, 2006, Pages 441-456

  Bhatnagar, Deepak ^a  

^a ROYAL OLDHAM HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANAMNESIS; CHOLESTEROL BLOOD LEVEL; CHROMOSOME BAND; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MASS SCREENING; METABOLISM; PATHOGENESIS; PATIENT MONITORING; PHENOTYPE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SCREENING; VALIDITY;

ADOLESCENT; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; MUTATION; PHENOTYPE; RECEPTORS, LDL;

EID: 33751319679     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456306778904641     Document Type: Review

References (187)

1. Ignatowski A. Uber die Wirkung des Tierischen Eiweisses auf die Aorta und die paerenchymatosen Organe der Kaninchen. Virchows Arch Pathol Anat 1909; 198: 248-70
2. Pedersen KO. The development of Svedberg's ultracentrifuge. Biophys Chem 1976; 5: 3-18
3. Gofman JW, De Lalla O, Glazier F, et al. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary artery disease. Plasma 1954; 2: 413-84
4. Burns FS. A contribution to the study of the etiology of xanthoma. Arch Derm Syph 1920; 2: 415-29
5. Muller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939; 64: 675-700
6. Thannhauser SJ, Magendanta H. The different clinical groups of xanthomatous diseases: a clinical physiological study of 22 cases. Ann Intern Med 1938; 11: 1662-746
7. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci USA 1973; 70: 2804-8
8. Brown MS, Goldstein JL. Receptor-mediated control of cholesterol metabolism. Science 1976; 191: 150-4
9. Goldstein JL, Brown MS. The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu Rev Genet 1979; 13: 259-89
10. The low density lipoprotein (LDLR) gene in familial hypercholesterolaemia. http://www.ucl.ac.uk/fh. Accessed 23 December 2005
11. Pullinger CR, Hennessy LK, Chatterton JE, et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995; 95: 1225-34
12. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-6
13. Eden ER, Naoumova RP, Burden JJ, et al. Use of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families. Am J Hum Genet 2001; 68: 653-60
14. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002; 110: 109-17
15. Lee MH, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietarycholesterol absorption. Nat Genet 2001; 27: 79-83
16. Rayer PFO. Traité Theorique et Pratiques des Maladies de la Peau. Paris: Balliere, 1836
17. Ranking WH. Case of vitilogoidea with remarks. Lancet 1853; i: 172-3
18. Fagge CH. General xanthelasma or vitiligoidea. Trans Path Soc Lond 1873; 24: 242-50
19. Shapiro JR, Fallat RW, Tsang RC, Glueck CJ. Achilles tendinitis and tenosynovitis. A diagnostic manifestation of familial type II hyperlipoproteinemia in children. Am J Dis Child 1974; 128: 486-90
20. Beeharry D, Coupe B, Benbow E, et al. Familial hypercholesterolaemia commonly presents with achilles tenosynovitis. Ann Rheum Dis 2006; 65: 312-15
21. Carranza-Bencano A, Fernadez-Centeno M, Leal-Cerro A, Duque-Jimeno V, Gomez-Arroyo JA, Zurita-Gutierrez M. Xanthomas of the Achilles tendon: report of a bilateral case and review of the literature. Foot Ankle Int 1999; 20: 314-16
22. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, et al. eds. The Metabolic and Molecular Basis of Inherited disease. 8th edn. New York: McGraw-Hill, 2001; 2863-913
23. Civeira F, Castillo S, Alonso R, et al., Spanish Familial Hypercholesterolemia Group. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol 2005; 25: 1960-5
24. Durrington PN, Adams JE, Beastall MD. The assessment of Achilles tendon size in primary hypercholesterolaemia by computed tomography. Atherosclerosis 1982; 45: 345-58
25. Junyent M, Gilabert R, Zambon D, et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol 2005; 25: 2203-8
26. Bude RO, Adler RS, Bassett DR. Diagnosis of Achilles tendon xanthoma in patients with heterozygous familial hypercholesterolemia: MR vs sonography. Am J Roentgenol 1994; 162: 913-17
27. Liem MS, Leuven JA, Bloem JL, Schipper J. Magnetic resonance imaging of Achilles tendon xanthomas in familial hypercholesterolemia. Skeletal Radio 1992; 21: 453-7
28. Fielder AR, Winder AF, Sheraidah GA, Cooke ED. Problems with corneal arcus. Trans Ophthalmol Soc UK 1981; 101: 22-6
29. Beppu S, Minura Y, Sakakibara H, et al. Supravalvular aortic stenosis and coronary ostial stenosis in familial hypercholesterolemia: two-dimensional echocardiographic assessment. Circulation 1983; 67: 878-84
30. Goldstein JL. The cardiac manifestations of the homozygous and heterozygous forms of familial type II hypercholesterolaemia. Birth Defects 1972; 8: 202
31. Durrington PN. Diagnosis and management. In: Hyperlipidaemia. Oxford: Butterworth Heinemannn, 1995: 116
32. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 2004; 13(Spec No 1): R149-60
33. Hopkins PN, Wu LL, Schumacher MC, et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb 1991; 11: 1137-46
34. Carmena R, Roy M, Roederer G, Minnich A, Davignon J. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. Atherosclerosis 2000; 148: 113-24
35. Klemp P, Halland AM, Majoos FL, Steyn K. Musculoskeletal manifestations in hyperlipidaemia: a controlled study. Ann Rheum Dis 1993; 52: 44-8
36. Mathon G, Gagne C, Brun D, Lupien PJ, Moorjani S. Articular manifestations of familial hypercholesterolaemia. Ann Rheum Dis 1985; 44: 599-602
37. Khachadurian AK. Migratory polyarthritis in familial hypercholesterolemia (type II hyperlipoproteinemia). Arthritis Rheum 1968; 11: 385-93
38. Rooney PJ, Third J, Madkour MM, Spencer D, Dick WC. Transient polyarthritis associated with familial hyperbetalipoproteinaemia. Q J Med 1978; 47: 249-59
39. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004; 160: 421-9
40. Hutter CM, Austin MA, Humphries SE. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am J Epidemiol 2004; 160: 430-5
41. Huxley RR, Hawkins MH, Humphries SE, Karpe F, Neil HA, Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke 2003; 34: 22-5. Erratum in: Stroke 2003; 34: 826
42. Sprecher DL, Schaefer EJ, Kent KM, et al. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol 1984; 54: 20-30
43. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160: 407-20
44. Austin MA, Zimmern RL, Humphries SE. High 'population attributable fraction' for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia. Genet Med 2002; 4: 275-8
45. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49: 476-88
46. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; ii: 1380-2
47. Jensen J, Blankenhorn DH, Kornerup V. Coronary disease in familial hypercholesterolaemia. Circulation 1967; 36: 77-82
48. Heiberg A. The risk of atherosclerotic vascular disease in subjects with xanthomatosis. Acta Med Scand 1975; 198: 249-61
49. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 290-7
50. Beaumont V, Jacotot B, Beaumont JL. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. Atherosclerosis 1976; 24: 441-50
51. Sijbrands EJ, Westendorp RG, Defesche JC, et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001; 322: 1019-23
52. Mabuchi H, Miyamoto S, Ueda K, et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986; 61: 1-6
53. Sun XM, Patel DD, Bhatnagar D, et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. Arterioscler Thromb Vasc Biol 1995; 15: 219-27
54. Gudnason V, Day IN, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1717-22
55. Vuorio AF, Aalto-Setala K, Koivisto UM, et al. Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group. Ann Med 2001; 33: 410-21
56. Koeijvoets KC, Wiegman A, Rodenburg J, Defesche JC, Kastelein JJ, Sijbrands EJ. Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. Atherosclerosis 2005; 180: 93-9
57. Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005; 25: 2654-60
58. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256: 482-90
59. Jadhav AV, Thompson GR. Reversible abnormalities of low density lipoprotein composition in familial hypercholesterolaemia. Eur J Clin Invest 1979; 9: 63-7
60. Soutar AK, Myant NB, Thompson GR. Simultaneous measurement of apolipoprotein B turnover in very-low and low-density lipoproteins in familial hypercholesterolaemia. Atherosclerosis 1977; 28: 247-56
61. Streja D, Steiner G, Kwiterovich Jr PO. Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann Intern Med 1978; 89: 871-80
62. Mbewu AD, Bhatnagar D, Durrington PN, et al. Serum lipoprotein (a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991; 11: 940-6
63. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989; 86: 4171-4
64. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein (a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494-9
65. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27-38
66. Lindgren V, Luskey KL, Russell DW, Francke U. Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. Proc Natl Acad Sci USA 1985; 82: 8567-71
67. Schneider WJ, Beisiegel U, Goldstein JL, Brown MS. Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight. J Biol Chem 1982; 257: 2664-73
68. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276: 34-42
69. Langer T, Strober W, Levy RI. The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest 1972; 51: 1528-36
70. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-61
71. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974; 249: 5153-62
72. Berg K, Heiberg A. Linkage between familial hypercholesterolemia with xanthomatosis and the C3 polymorphism confirmed. Cytogenet Cell Genet 1978; 22: 621-3
73. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
74. Myant NB, Gallagher JJ, Knight BL, et al. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arterioscler Thromb 1991; 11: 691-703
75. Kaprio J. The role of other genes and environment should not be overlooked in monogenic disease. BMJ 2001; 322: 1023
76. Cai HJ, Fan LM, Huang MG, Chen XY, Liu GQ, Chen Q. Homozygous familial hypercholesterolemic patients in China. Atherosclerosis 1985; 57: 303-12
77. Thompson GR, Seed M, Niththyananthan S, McCarthy S, Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 1989; 9(1 Suppl): I75-80
78. Eto M, Watanabe K, Chonan N, Ishii K. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 1988; 72: 123-8
79. Gylling H, Miettinen TA. Serum noncholesterol sterols related to cholesterol metabolism in familial hypercholesterolemia. Clin Chim Acta 1988; 178: 41-9
80. Sugrue DD, Thompson GR, Oakley CM, Trayner IM, Steiner RE. Contrasting patterns of coronary atherosclerosis in normocholesterolaemic smokers and patients with familial hypercholesterolaemia. BMJ 1981; 283: 1358-60
81. Wiegman A, Rodenburg J, de Jongh S, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003; 25: 1473-8
82. Graham CA, McClean E, Ward AJ, et al. Mutation screening and genotype:phenotype correlation in familial hypercholesterolaemia. Atherosclerosis 1999; 147: 309-16
83. Kotze MJ, De Villiers WJ, Steyn K, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993; 13: 1460-8
84. Vohl MC, Gaudet D, Moorjani S, et al. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest 1997; 27: 366-73
85. Gaudet D, Vohl MC, Couture P, et al. Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. Atherosclerosis 1999; 143: 153-61
86. Bertolini S, Cantafora A, Averna M, et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 2000; 20: E41-52
87. Tonstad S, Leren TP, Sivertsen M, et al. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol 1995; 15: 1009-14
88. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, et al. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106: 3031-6
89. Gudnason V, Day IN, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1717-22
90. Duly EB, Ward AJ, Kirk CW, et al. APO E genotype and familial hypercholesterolaemia. Ann Clin Biochem 1997; 34: 534-6
91. Friedlander Y, Leitersdorf E. Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia. Genet Epidemiol 1996; 13: 159-77
92. Wittekoek ME, Moll E, Pimstone SN, et al. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 192: 708-13
93. Zambon A, Torres A, Bijvoet S, et al. Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. Lancet 1993; 341: 1119-21
94. de Grooth GJ, Smilde TJ, Van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004; 173: 261-7
95. Carmena-Ramon R, Ascaso JF, Real JT, Najera G, Ordovas JM, Carmena R. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and plasma lipoprotein levels in familial hypercholesterolemia. Metabolism 2001; 50: 651-6
96. Lundahl B, Leren TP, Ose L, Hamsten A, Karpe F. A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP-493G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1784-8
97. Bertolini S, Pisciotta L, Di Scala L, et al. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 2004; 174: 57-65
98. Pisciotta L, Cortese C, Gnasso A, et al. Serum homocysteine, methylenetetrahydrofolate reductase gene polymorphism and cardiovascular disease in heterozygous familial hypercholesterolemia. Atherosclerosis 2005; 179: 333-8
99. Cenarro A, Artieda M, Castillo S, et al. Spanish FH group. A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. J Med Genet 2003; 40: 163-8
100. Wierzbicki AS, Lambert-Hammill M, Lumb PJ, Crook MA. Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia. Hypertension 2000; 36: 808-12
101. Leus FR, Wittekoek ME, Prins J, Kastelein JJ, Voorbij HA. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 2000; 149: 371-7
102. Roest M, Jansen AC, Barendrecht A, Leus FR, Kastelein JJ, Voorbij HA. Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia. Clin Biochem 2005; 38: 123-7
103. Haba T, Sakai Y, Koizumi J, Miyamoto S, Mabuchi H, Takeda R. A case of heterozygous familial hypercholesterolemia associated with hyperthyroidism: effects of triiodothyronine on low-density lipoprotein receptor and cholesterol synthesis. Metabolism 1983; 32: 1129-32
104. Inukai T, Takanashi K, Takebayashi K, et al. Estrogen markedly increases LDL-receptor activity in hypercholesterolemic patients. J Med 2000; 3: 247-61
105. Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005; 51: 2067-73
106. Hogue JC, Lamarche B, Gaudet D, et al. Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial hypercholesterolemia. Atherosclerosis 2006; 184: 163-70
107. Real JT, Chaves FJ, Martinez-Uso I, Garcia-Garcia AB, Ascaso JF, Carmena R. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur Heart J 2001; 22: 465-71
108. Dane-Stewart CA, Watts GF, Mamo JC, Dimmitt SB, Barrett PH, Redgrave TG. Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. Eur J Clin Invest 2001; 31: 113-17
109. Neil HA, Seagroatt V, Betteridge DJ, et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 2004; 90: 1431-7
110. Hegele RA. Environmental modulation of artherosclerosis end points in familial hypercholesterolemia. Atheroscler Suppl 2002; 2: 5-7
111. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001; 322: 1019-23
112. Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 1998; 18: 309-15
113. Pereira E, Ferreira R, Hermelin B, et al. Recurrent and novel LDL receptor gene mutations causing heterozygous familial hypercholesterolemia in La Habana. Hum Genet 1995; 96: 319-22
114. Pauciullo P, Giannino A, De Michele M, et al. Increased carotid artery intima-media thickness is associated with a novel mutation of low-density lipoprotein receptor independently of major cardiovascular risk factors. Metabolism 2003; 52: 1433-8
115. Descamps OS, Gilbeau JP, Luwaert R, Heller FR. Impact of genetic defects on coronary atherosclerosis in patients suspected of having familial hypercholesterolaemia. Eur J Clin Invest 2003; 33: 1-9
116. Butler JR. Economic evaluations of screening programs: a review of methods and results. Clin Chim Acta 2002; 315: 31-40
117. Wilson JM, Jungner G. Principles and Practice of Screening for Disease. (Public Health Paper Number 34). Geneva: World Health Organization, 1968
118. McQueen MJ. Screening for the early detection of disease, the need for evidence. Clin Chim Acta 2002; 315: 5-15
119. Burnett JR, Ravine D, van Bockxmeer FM, Watts GF. Familial hypercholesterolaemia: a look back, a look ahead. Med J Aust 2005; 182: 552-3
120. Thompson GR. Screening relatives of patients with premature coronary heart disease. Heart 2002; 87: 390-4
121. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303: 893-6
122. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6
123. World Health Organization. Familial hypercholesterolaemia; Report of a Second WHO Consultation, WHO/HGN/FH/CONS/99.2. Geneva: WHO, 1999
124. Skovby F, Micic S, Jepsen B, et al. Screening for familial hypercholesterolaemia by measurement of apolipoproteins in capillary blood. Arch Dis Child 1991; 66: 844-7
125. Williams RR, Schumacher MC, Barlow GK, et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993; 72: 18D-24D
126. Junyent M, Gilabert R, Zambon D, et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol 2005; 25: 2203-8
127. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 2004; 66: 483-7
128. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000; 321: 1497-500
129. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357: 165-8
130. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet 2001; 109: 602-15
131. Leren TP, Manshaus T, Skovholt U, et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin Vasc Med 2004; 4: 75-85
132. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol 2003; 23: 335-8
133. Marteau TM, Croyle RT. The new genetics. Psychological responses to genetic testing. BMJ 1998; 316: 693-6
134. Andersen LK, Jensen HK, Juul S, Faergeman O. Patients' attitudes towards detection of heterozygous familial hypercholesterolaemia. Arch Intern Med 1997; 157: 553-60
135. Senior V, Marteau TM, Peters TJ. Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents responses to neonatal screening for familial hypercholesterolaemia. Soc Sci Med 1999; 48: 1857-60
136. Newson AJ, Humphries SE. Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet 2005; 13: 401-8
137. Gibbons SM, Helgason HH, Kaye J, Nomper A, Wendel L. Lessons from European population genetic databases: comparing the law in Estonia, Iceland, Sweden and the United Kingdom. Eur J Health Law 2005; 12: 103-33
138. Hadfield SG, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol 2005; 16: 428-33
139. Wilcke JT. Late onset genetic disease: where ignorance is bliss, is it folly to inform relatives? BMJ 1998; 317: 744-7
140. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-6
141. Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001; 5: 107-10
142. van Maarle MC, Stouthard ME, Bonsel GJ. Risk perception of participants in a family-based genetic screening program on familial hypercholesterolemia. Am J Med Genet A 2003; 116: 136-43
143. Neil HA, Hammond T, Mant D, Humphries SE. Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ 2004; 328: 500-1
144. Neil HA, Mant D. Cholesterol screening and life assurance. BMJ 1991; 302: 891-3
145. Low L, King S, Wilkie T. Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom. BMJ 1998; 317: 1632-5
146. Delatycki M, Allen K, Williamson R. Insurance agreement to facilitate genetic testing. Lancet 2002; 359: 1433
147. Raithatha N, Smith RD. Disclosure of genetic tests for health insurance: is it ethical not to? Lancet 2004; 363: 395-6
148. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005; 180: 155-60
149. Patch C, Roderick P, Rosenberg W. Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: assessment of anxiety, depression, and perception of health. Genet Med 2005; 7: 550-6
150. Gaudet D, Gagné C, Perron P, Couture P, Tonstad S. Ethical issues in molecular screening for heterozygous familial hypercholesterolemia: the complexity of dealing with genetic susceptibility to coronary artery disease. Commun Genet 1999; 2: 2-8
151. Green MJ, Botkin JR. 'Genetic exceptionalism' in medicine: clarifying the differences between genetic and nongenetic tests. Ann Intern Med 2003; 138: 571-5
152. McCune CA, Ravine D, Worwood M, Jackson HA, Evans HM, Hutton D. Screening for hereditary haemochromatosis within families and beyond. Lancet 2003; 362: 1897-8
153. Patch C, Roderick P, Rosenberg W. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis. J Hepatol 2005; 43: 149-55
154. Olynyk JK, Trinder D, Milward E. Hereditary haemochromatosis: to screen or not to screen? J Hepatol 2005; 43: 9-10
155. Muller PY, Miserez AR. Large heterogeneity of mutations in the gene encoding the low-density lipoprotein receptor in subjects with familial hypercholesterolaemia. Atheroscler Suppl 2004; 5: 1-5
156. Sozen M, Whittall R, Humphries SE. Mutation detection in patients with familial hypercholesterolaemia using heteroduplex and single strand conformation polymorphism analysis by capillary electrophoresis. Atheroscler Suppl 2004; 5: 7-11
157. Graham CA, McIlhatton BP, Kirk CW, et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 2005; 182: 331-40
158. Wang J, Ban MR, Hegele RA. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J Lipid Res 2005; 46: 366-72
159. Damgaard D, Nissen PH, Jensen LG, et al. Detection of large deletions in the LDL receptor gene with quantitative PCR methods. BMC Med Genet 2005; 6: 15
160. Kohane IS, Altman RB. Health-information altruists - a potentially critical resource. N Engl J Med 2005; 353: 2074-7
161. Fouchier SW, Kastelein JJ, Defesche JC. Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum Mutat 2005; 26: 550-6
162. Defesche JC, Lansberg PJ, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med 2004; 4: 59-65
163. Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med 2004; 4: 67-74
164. Civeira F, International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55-68
165. Laurie AD, Scott RS, George PM. Genetic screening of patients with familial hypercholesterolaemia (FH): a New Zealand perspective. Atheroscler Suppl 2004; 5: 13-15
166. Jensen HK. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Dan Med Bull 2002; 49: 318-45
167. Brorholt-Petersen JU, Jensen HK, Jensen JM, et al. LDL receptor mutation genotype and vascular disease phenotype in heterozygous familial hypercholesterolaemia. Clin Genet 2002; 61: 408-15
168. European Society of Human Genetics' PPPC. Provision of genetic services in Europe: current practices and issues. Eur J Hum Genet 2003; 11: 900-2
169. European Society of Human Genetics' PPPC. Population genetic screening programmes: technical, social and ethical issues. Eur J Hum Genet 2003; 11: 903-5
170. European Society of Human Genetics' PPPC. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet 2003; 11: 909-10
171. Donnai D, Elles R. Integrated regional genetic services: current and future provision. BMJ 2001; 322: 1048-52
172. Gluud C, Gluud LL. Evidence based diagnostics. BMJ 2005; 330: 724-6
173. Sanderson S, Zimmern R, Kroese M, Higgins J, Patch C, Emery J. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med 2005; 7: 495-500
174. Raggi CC, Pinzani P, Paradiso A, Pazzagli M, Orlando C. External quality assurance program for PCR amplification of genomic DNA: an Italian experience. Clin Chem 2003; 49: 782-91
175. Richards CS, Grody WW. Alternative approaches to proficiency testing in molecular genetics. Clin Chem 2003; 49: 717-18
176. Goldman L, Goldman PA, Williams LW, et al. Cost-effectiveness
177. Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003; 163: 65-8
178. Mohrschladt MF, Westendorp RG, Gevers Leuven JA, Smelt AH. Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 2004; 172: 329-35
179. Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004; 4: 97-104
180. Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, et al. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in the Netherlands. Eur Heart J 2002; 23: 1922-30
181. Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000; 4: 1-123
182. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002; 324: 1303-8
183. Starr B, Hutten B, Hadfield G, Lansberg P, Humphries SE. Development of, age-specific LDL-cholesterol (LDL-C) criteria for diagnosis in familial hypercholesterolaemia (FH) families. Accessed at http://www.fhcascade.org.uk/
184. Institute for Clinical Systems Improvement (ICSI). Lipid screening in children and adolescents. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI). Accessed at http://www.guideline.gov/summary/summary.aspx? view_id=1&doc_id=5453&nbr=3730 June 2004
185. Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol 1997; 17: 3127-38
186. Wiegman A, Sijbrands EJ, Rodenburg J, et al. The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia. Pediatr Res 2003; 53: 1008-12
187. Mozas P, Castillo S, Reyes G, et al. Spanish group FH. Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. Am Heart J 2003; 145: 999-1005